NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

23.20 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 08, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 07, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

7 Analysts Have This To Say About NewAmsterdam Pharma ↗

February 27, 2025

Via Benzinga

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) ↗

January 24, 2025

Via Benzinga

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

April 30, 2025

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 22, 2025

Via Benzinga

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

April 17, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Where NewAmsterdam Pharma Stands With Analysts ↗

December 30, 2024

Via Benzinga

The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts ↗

April 08, 2025

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 26, 2025

Via Benzinga

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

February 26, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

February 26, 2025

Via Benzinga

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

February 25, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

January 29, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 16, 2025

Via Benzinga

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

January 10, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗

December 15, 2024

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.

Via Benzinga

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

December 13, 2024

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 11, 2024

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

Top 3 Health Care Stocks That May Collapse This Quarter ↗

December 11, 2024

Via Benzinga

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 10, 2024

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 10, 2024

Via Benzinga

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? ↗

December 10, 2024

NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy.

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday ↗

December 10, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.